Literature DB >> 21781173

Increased plasma chymase concentration and mast cell chymase expression in venous neointimal lesions of patients with CKD and ESRD.

Haimanot Wasse1, Angel A Rivera, Rong Huang, Deborah E Martinson, Qi Long, William McKinnon, Nawazish Naqvi, Ahsan Husain.   

Abstract

The underlying inflammatory component of chronic kidney disease may predispose blood vessels to intimal hyperplasia (IH), which is the primary cause of dialysis access failure. We hypothesize that vascular pathology and markers of IH formation are antecedent to arteriovenous (AV) fistula creation. Blood, cephalic, and basilic vein segments were collected from predialysis chronic kidney disease (CKD) patients with no previous AV access and patients with end-stage renal disease (ESRD). Immunohistochemistry was performed with antibodies against mast cell chymase, transforming growth factor-beta (TGF-β) and interleukin-6 (IL-6), which cause IH. Plasma chymase was measured by ELISA. IH was present in 91% of CKD and 75% of ESRD vein segments. Chymase was abundant in vessels with IH, with the greatest expression in intima and medial layers, and virtually absent in the controls. Chymase colocalized with TGF-β1 and IL-6. Plasma chymase concentration was elevated up to 33-fold in patients with CKD versus controls and was associated with increased chymase in vessels with IH. We show that chymase expression in vessels with IH corresponds with plasma chymase concentrations. As chymase inhibition attenuates IH in animal models, and we find chymase is highly expressed in IH lesions of patients with CKD and ESRD, we speculate that chymase inhibition could have therapeutic value in humans.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21781173      PMCID: PMC3212616          DOI: 10.1111/j.1525-139X.2011.00921.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  43 in total

1.  A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[,4-dioxo-1-phenyl-7-(2-pyridyloxy)]2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury.

Authors:  Shinji Takai; Hiroshi Sakonjo; Kohzo Fukuda; Denan Jin; Masato Sakaguchi; Keiichi Kamoshita; Koichi Ishida; Yoshikazu Sukenaga; Mizuo Miyazaki
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

2.  Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II.

Authors:  G H Gibbons; R E Pratt; V J Dzau
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 3.  Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation.

Authors:  Franck Verrecchia; Alain Mauviel
Journal:  J Invest Dermatol       Date:  2002-02       Impact factor: 8.551

4.  Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation.

Authors:  M Nishimoto; S Takai; S Kim; D Jin; A Yuda; M Sakaguchi; M Yamada; Y Sawada; K Kondo; K Asada; H Iwao; S Sasaki; M Miyazaki
Journal:  Circulation       Date:  2001-09-11       Impact factor: 29.690

5.  Venous stenoses in patients who undergo hemodialysis: treatment with self-expandable endovascular stents.

Authors:  S F Quinn; E S Schuman; L Hall; G F Gross; B T Uchida; B A Standage; J Rosch; K Ivancev
Journal:  Radiology       Date:  1992-05       Impact factor: 11.105

6.  Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism.

Authors:  S A Griffin; W C Brown; F MacPherson; J C McGrath; V G Wilson; N Korsgaard; M J Mulvany; A F Lever
Journal:  Hypertension       Date:  1991-05       Impact factor: 10.190

7.  Transforming growth factor beta1 genotype polymorphisms determine AV fistula patency in hemodialysis patients.

Authors:  Gunnar H Heine; Christof Ulrich; Urban Sester; Martina Sester; Hans Köhler; Matthias Girndt
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

8.  Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or on clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).

Authors:  W R Hermans; B J Rensing; D P Foley; J W Deckers; W Rutsch; H Emanuelsson; N Danchin; W Wijns; F Chappuis; P W Serruys
Journal:  J Am Coll Cardiol       Date:  1992-10       Impact factor: 24.094

9.  Role of transforming growth factor-beta 1 in the cellular growth response to angiotensin II.

Authors:  Y Koibuchi; W S Lee; G H Gibbons; R E Pratt
Journal:  Hypertension       Date:  1993-06       Impact factor: 10.190

10.  Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall.

Authors:  M J Daemen; D M Lombardi; F T Bosman; S M Schwartz
Journal:  Circ Res       Date:  1991-02       Impact factor: 17.367

View more
  13 in total

1.  Objectives and design of the hemodialysis fistula maturation study.

Authors:  Laura M Dember; Peter B Imrey; Gerald J Beck; Alfred K Cheung; Jonathan Himmelfarb; Thomas S Huber; John W Kusek; Prabir Roy-Chaudhury; Miguel A Vazquez; Charles E Alpers; Michelle L Robbin; Joseph A Vita; Tom Greene; Jennifer J Gassman; Harold I Feldman
Journal:  Am J Kidney Dis       Date:  2013-08-28       Impact factor: 8.860

Review 2.  Novel paradigms for dialysis vascular access: downstream vascular biology--is there a final common pathway?

Authors:  Timmy Lee
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

3.  Novel paradigms for dialysis vascular access: Introduction.

Authors:  Michael Allon
Journal:  Clin J Am Soc Nephrol       Date:  2013-12       Impact factor: 8.237

4.  Preexisting venous calcification prior to dialysis vascular access surgery.

Authors:  Timmy Lee; Nida Safdar; Meenakshi J Mistry; Yang Wang; Vibha Chauhan; Begoña Campos; Rino Munda; Virgilius Cornea; Prabir Roy-Chaudhury
Journal:  Semin Dial       Date:  2012-03-27       Impact factor: 3.455

5.  Correlation of pre-existing vascular pathology with arteriovenous graft outcomes in hemodialysis patients.

Authors:  Michael Allon; Silvio Litovsky; Carlton J Young; Mark H Deierhoi; Jeremy Goodman; Michael Hanaway; Mark E Lockhart; Michelle L Robbin
Journal:  Am J Kidney Dis       Date:  2013-06-05       Impact factor: 8.860

6.  Alpha-1 antitrypsin, a diagnostic and prognostic marker of vernal keratoconjunctivitis.

Authors:  Akif Ahsan; Khushtar A Salman; Sana Alam; Anwar H Siddiqui; Syed Shariq Naeem; Aquil Ahmad; Iqbal M Khan
Journal:  J Clin Diagn Res       Date:  2014-05-15

Review 7.  Mast cells in human and experimental cardiometabolic diseases.

Authors:  Guo-Ping Shi; Ilze Bot; Petri T Kovanen
Journal:  Nat Rev Cardiol       Date:  2015-08-11       Impact factor: 32.419

8.  Impact of Mast Cell Chymase on Renal Disease Progression.

Authors:  Haimanot Wasse; Nawazish Naqvi; Ahsan Husain
Journal:  Curr Hypertens Rev       Date:  2012-02-01

9.  Comparative analysis of cellular phenotypes within the neointima from vein segments collected prior to vascular access surgery and stenotic arteriovenous dialysis accesses.

Authors:  Timmy Lee; Yang Wang; Lois Arend; Virgilius Cornea; Begona Campos; Rino Munda; Prabir Roy-Chaudhury
Journal:  Semin Dial       Date:  2013-12-17       Impact factor: 3.455

Review 10.  Optimal hemodialysis vascular access in the elderly patient.

Authors:  Louise M Moist; Charmaine E Lok; Tushar J Vachharajani; Wang Xi; Ahmed AlJaishi; Kevan R Polkinghorne; Miguel Vazquez; Timmy C Lee
Journal:  Semin Dial       Date:  2012 Nov-Dec       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.